Sagent Pharmaceuticals, Inc., Schaumburg, Ill., on June 11 announced a voluntary nationwide recall of three lots of vecuronium bromide for injection 10 mg (NDC number 25021-657-10).
Sagent Pharmaceuticals, Inc., Schaumburg, Ill., on June 11 announced a voluntary nationwide recall of three lots of vecuronium bromide for injection 10 mg (NDC number 25021-657-10).
The lots, manufactured by Mustafa Nevzat Ilac Sanayii A.S. (MN Pharmaceuticals) and distributed by Sagent, were recalled following the discovery of an elevated impurity result detected during routine quality testing of stability samples at the 18-month interval.
According to Sagent, the elevated impurity result can cause prolonged neuromuscular blockade for critically ill patients with renal failure.
The lot numbers being recalled are: 11I30481A, 11I30721A and 11I32581A, which were distributed to hospitals, wholesalers, and distributors nationwide from January 2012 through May 2012.
Healthcare professionals are being asked to examine their inventory and to quarantine, discontinue distribution of, and return all recalled lots of the product to Sagent. Healthcare workers with medical questions about vecuronium bromide for injection can call 866-625-1618.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the product. Consumers can call Sagent at 866 625-1618.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.